BACKGROUND AND PURPOSE: The cause of developmental delay frequently is unknown, and clinicians and families can be frustrated by the lack of neuroimaging correlation especially when considering therapeutic options and long-term prognosis. We sought to determine if proton MR spectroscopy can depict abnormalities in patients with developmental delay who have structurally normal brain MR images. METHODS: Children with developmental delay who were older than 2 years (mean age, 5.0 years; range, 3.0-10.0 years) and those aged 2 years or younger (mean age, 1.5 years; range, 0.5-2.0 years) and age-matched control subjects for each patient group underwent brain MR imaging and proton MR spectroscopy. A point-resolved spectroscopy sequence (2000/144 [TR/TE]) was used. Voxels (8 cm(3)) were placed in the subcortical white matter of the frontal and parieto-occipital lobes bilaterally. N-acetylaspartate (NAA)/creatine (Cr) and choline (Cho)/Cr ratios were assessed. RESULTS: All patients had normal brain MR images. In children with developmental delay who were aged 2 years or younger, no statistically significant differences were detected in the NAA/Cr or Cho/Cr ratios compared with those of the control subjects. In children with developmental delay who were older than 2 years, decreases in the NAA/Cr ratio were observed in frontal (P <.001) and parieto-occipital (P <.017) subcortical white matter, and elevations in the Cho/Cr ratio were detected in the frontal (P <.24) and parieto-occipital (P <.002) subcortical white matter compared with age-matched control subjects. CONCLUSIONS: In children with developmental delay who are older than 2 years, proton MR spectroscopy depicted abnormalities in the NAA/Cr and Cho/Cr ratios. Proton MR spectroscopy should be performed as part of the neuroimaging evaluation of developmental delay. Further studies will be needed to determine if abnormalities detected with proton MR spectroscopy can be used as a diagnostic tool and neuroimaging marker to assess long-term functional outcome.
BACKGROUND AND PURPOSE: The cause of developmental delay frequently is unknown, and clinicians and families can be frustrated by the lack of neuroimaging correlation especially when considering therapeutic options and long-term prognosis. We sought to determine if proton MR spectroscopy can depict abnormalities in patients with developmental delay who have structurally normal brain MR images. METHODS:Children with developmental delay who were older than 2 years (mean age, 5.0 years; range, 3.0-10.0 years) and those aged 2 years or younger (mean age, 1.5 years; range, 0.5-2.0 years) and age-matched control subjects for each patient group underwent brain MR imaging and proton MR spectroscopy. A point-resolved spectroscopy sequence (2000/144 [TR/TE]) was used. Voxels (8 cm(3)) were placed in the subcortical white matter of the frontal and parieto-occipital lobes bilaterally. N-acetylaspartate (NAA)/creatine (Cr) and choline (Cho)/Cr ratios were assessed. RESULTS: All patients had normal brain MR images. In children with developmental delay who were aged 2 years or younger, no statistically significant differences were detected in the NAA/Cr or Cho/Cr ratios compared with those of the control subjects. In children with developmental delay who were older than 2 years, decreases in the NAA/Cr ratio were observed in frontal (P <.001) and parieto-occipital (P <.017) subcortical white matter, and elevations in the Cho/Cr ratio were detected in the frontal (P <.24) and parieto-occipital (P <.002) subcortical white matter compared with age-matched control subjects. CONCLUSIONS: In children with developmental delay who are older than 2 years, proton MR spectroscopy depicted abnormalities in the NAA/Cr and Cho/Cr ratios. Proton MR spectroscopy should be performed as part of the neuroimaging evaluation of developmental delay. Further studies will be needed to determine if abnormalities detected with proton MR spectroscopy can be used as a diagnostic tool and neuroimaging marker to assess long-term functional outcome.
Authors: S D Friedman; W M Brooks; R E Jung; S J Chiulli; J H Sloan; B T Montoya; B L Hart; R A Yeo Journal: Neurology Date: 1999-04-22 Impact factor: 9.910
Authors: E B Cady; J Penrice; P N Amess; A Lorek; M Wylezinska; R F Aldridge; F Franconi; J S Wyatt; E O Reynolds Journal: Magn Reson Med Date: 1996-12 Impact factor: 4.668
Authors: A J Barkovich; K Baranski; D Vigneron; J C Partridge; D K Hallam; B L Hajnal; D M Ferriero Journal: AJNR Am J Neuroradiol Date: 1999-09 Impact factor: 3.825
Authors: I Barić; M Cuk; K Fumić; O Vugrek; R H Allen; B Glenn; M Maradin; L Pazanin; I Pogribny; M Rados; V Sarnavka; A Schulze; S Stabler; C Wagner; S H Zeisel; S H Mudd Journal: J Inherit Metab Dis Date: 2005 Impact factor: 4.982
Authors: Paul D Griffiths; Ruth Batty; Daniel Warren; Anthony Hart; Mark Sharrard; Santosh R Mordekar; Ashok Raghavan; Daniel J A Connolly Journal: Eur Radiol Date: 2011-05-10 Impact factor: 5.315
Authors: Ashley Acheson; S Andrea Wijtenburg; Laura M Rowland; Bethany C Bray; Frank Gaston; Charles W Mathias; Peter T Fox; William R Lovallo; Susan N Wright; L Elliot Hong; Stephen McGuire; Peter Kochunov; Donald M Dougherty Journal: Hum Brain Mapp Date: 2014-07-21 Impact factor: 5.038
Authors: Dong-Hyun Kim; Meng Gu; Charles Cunningham; Albert Chen; Fiona Baumer; Orit A Glenn; Daniel B Vigneron; Daniel Mark Spielman; Anthony James Barkovich Journal: J Magn Reson Imaging Date: 2009-01 Impact factor: 4.813
Authors: E M Augustine; D M Spielman; P D Barnes; T L Sutcliffe; J D Dermon; M Mirmiran; D B Clayton; R L Ariagno Journal: J Perinatol Date: 2008-07-10 Impact factor: 2.521